RT Journal Article
SR Electronic
T1 A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations
JF Science Translational Medicine
FD American Association for the Advancement of Science
SP eabc3103
DO 10.1126/scitranslmed.abc3103
VO 12
IS 559
A1 Grzelak, Ludivine
A1 Temmam, Sarah
A1 Planchais, Cyril
A1 Demeret, Caroline
A1 Tondeur, Laura
A1 Huon, Christèle
A1 Guivel-Benhassine, Florence
A1 Staropoli, Isabelle
A1 Chazal, Maxime
A1 Dufloo, Jeremy
A1 Planas, Delphine
A1 Buchrieser, Julian
A1 Rajah, Maaran Michael
A1 Robinot, Remy
A1 Porrot, Françoise
A1 Albert, Mélanie
A1 Chen, Kuang-Yu
A1 Crescenzo-Chaigne, Bernadette
A1 Donati, Flora
A1 Anna, François
A1 Souque, Philippe
A1 Gransagne, Marion
A1 Bellalou, Jacques
A1 Nowakowski, Mireille
A1 Backovic, Marija
A1 Bouadma, Lila
A1 Le Fevre, Lucie
A1 Le Hingrat, Quentin
A1 Descamps, Diane
A1 Pourbaix, Annabelle
A1 Laouénan, Cédric
A1 Ghosn, Jade
A1 Yazdanpanah, Yazdan
A1 Besombes, Camille
A1 Jolly, Nathalie
A1 Pellerin-Fernandes, Sandrine
A1 Cheny, Olivia
A1 Ungeheuer, Marie-Noëlle
A1 Mellon, Guillaume
A1 Morel, Pascal
A1 Rolland, Simon
A1 Rey, Felix A.
A1 Behillil, Sylvie
A1 Enouf, Vincent
A1 Lemaitre, Audrey
A1 Créach, Marie-Aude
A1 Petres, Stephane
A1 Escriou, Nicolas
A1 Charneau, Pierre
A1 Fontanet, Arnaud
A1 Hoen, Bruno
A1 Bruel, Timothée
A1 Eloit, Marc
A1 Mouquet, Hugo
A1 Schwartz, Olivier
A1 van der Werf, Sylvie
YR 2020
UL http://stm.sciencemag.org/content/12/559/eabc3103.abstract
AB Individuals infected with SARS-CoV-2 mount an antibody response that may vary depending on the severity of the disease. Grzelak et al. assessed the amounts of anti–SARS-CoV-2 antibodies in serum samples from 491 healthy individuals before the pandemic, 51 individuals hospitalized with COVID-19, 209 suspected cases of COVID-19 with mild symptoms, and 200 healthy blood donors. The authors developed and compared the performance of four different serological assays measuring antibody amounts and their neutralizing activity. The assays enabled a broad evaluation of SARS-CoV-2 seroprevalence and antibody profiling in asymptomatic, mildly symptomatic, and severe cases of COVID-19.It is of paramount importance to evaluate the prevalence of both asymptomatic and symptomatic cases of SARS-CoV-2 infection and their differing antibody response profiles. Here, we performed a pilot study of four serological assays to assess the amounts of anti–SARS-CoV-2 antibodies in serum samples obtained from 491 healthy individuals before the SARS-CoV-2 pandemic, 51 individuals hospitalized with COVID-19, 209 suspected cases of COVID-19 with mild symptoms, and 200 healthy blood donors. We used two ELISA assays that recognized the full-length nucleoprotein (N) or trimeric spike (S) protein ectodomain of SARS-CoV-2. In addition, we developed the S-Flow assay that recognized the S protein expressed at the cell surface using flow cytometry, and the luciferase immunoprecipitation system (LIPS) assay that recognized diverse SARS-CoV-2 antigens including the S1 domain and the carboxyl-terminal domain of N by immunoprecipitation. We obtained similar results with the four serological assays. Differences in sensitivity were attributed to the technique and the antigen used. High anti–SARS-CoV-2 antibody titers were associated with neutralization activity, which was assessed using infectious SARS-CoV-2 or lentiviral-S pseudotype virus. In hospitalized patients with COVID-19, seroconversion and virus neutralization occurred between 5 and 14 days after symptom onset, confirming previous studies. Seropositivity was detected in 32% of mildly symptomatic individuals within 15 days of symptom onset and in 3% of healthy blood donors. The four antibody assays that we used enabled a broad evaluation of SARS-CoV-2 seroprevalence and antibody profiling in different subpopulations within one region.